SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~June~~August 2025

Commission file number: 001-35223

_______________________

BioLineRx Ltd.

(Translation of registrant’s name into English)

~~_______________________~~2 HaMa’ayan Street

~~2 HaMa’ayan Street~~ Modi’in 7177871, Israel

(Address of Principal Executive Offices)

_______________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

~~BioLineRx~~On ~~Ltd.~~August (14, 2025, the ~~“Company”)~~Registrant ~~today announced~~issued ~~the~~a press release announcing its financial results offor the ~~Company’s~~three ~~Annual~~and ~~General~~six ~~Meeting~~months ofended ~~Shareholders~~June ~~(the~~30, ~~“Meeting”)~~2025. The Registrant is also publishing its unaudited interim consolidated financial statements, ~~which~~as ~~was~~well ~~held~~as onits operating and financial review, as of June 2930, 2025, atand ~~3:00~~for ~~p.m.~~the ~~(Israel~~three ~~time)~~and six months then ended. Attached hereto are the following exhibits:

At the Meeting, the Company’s shareholders voted upon and approved, by the respective requisite majority in accordance with the Israel Companies Law, 5759-1999 and the Company’s articles of association (the “Articles of Association”), the proposals set forth in the Company’s proxy statement for the Meeting, which was attached as Exhibit ~~99.~~1: ~~to the Company~~Registrant’s ~~Report~~press onrelease ~~Form~~dated ~~6-K~~August ~~furnished to the U.S. Securities and Exchange Commission on May 23~~14, 2025~~. Accordingly, the following proposals were adopted at the Meeting:~~;

~~Proposal~~Exhibit 12: –Registrant’s ~~the~~condensed ~~re-election~~consolidated ofinterim ~~Dr.~~financial BJstatements ~~Bormann and Dr. Raphael Hofstein~~ as ~~Class~~of IIJune ~~directors~~30, ~~each~~2025 toand ~~serve~~for ~~until~~ the ~~Company’s annual~~three ~~general meeting of shareholders to be held in 2028,~~ and ~~until~~six ~~their~~months ~~respective~~then ~~successors~~ended; ~~have been duly elected~~ and ~~qualified.~~

~~Proposal~~Exhibit 23: –Registrant’s ~~the~~operating ~~increase~~and infinancial ~~the~~review ~~Company’s~~as ~~authorized~~of ~~share~~June ~~capital~~30, 2025 and tofor ~~amend~~ the ~~Company’s~~three ~~Articles~~and ofsix ~~Association~~months ~~accordingly~~then ended.

~~Proposal~~This 3Form –6-K, the ~~adoption~~text ofunder the ~~renewed~~heading ~~Compensation~~“Financial ~~Policy~~Results for the ~~Company’s~~Quarter ~~Executive~~Ended ~~Officers~~June 30, 2025” in Exhibit 1, Exhibit 2 and ~~Directors~~Exhibit 3 are hereby incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933.

Proposal 4 – the reappointment of Kesselman & Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, as the Company’s independent registered public accounting firm for the year ending December 31, 2025, and until the Company’s next annual general meeting of shareholders, and to authorize the Audit Committee of the Board of Directors to fix the compensation of said auditors in accordance with the scope and nature of their services

This Form 6-K is hereby incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BioLineRx Ltd.

	By:	/s/ Philip A. Serlin
		Philip A. Serlin
		Chief Executive Officer

Dated: ~~June~~August 3014, 2025

Filing Compare · BioLineRx Ltd.